First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Authors: Neda Laiteerapong, Jason Alexander, Louis Philipson, Aaron N. Winn, Elbert S. Huang
Journal: Annals of Internal Medicine (2023)

LettersApril 2023First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor AgonistsNeda Laiteerapong, MD, MS, Jason Alexander, MD, Louis Philipson, MD, PhD, Aaron N. Winn, PhD, Elbert S. Huang, MD, MPHNeda Laiteerapong, MD, MSSection of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, IllinoisSearch for more papers by this author, Jason Alexander, MDSection of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, IllinoisSearch for more papers by this author, Louis Philipson, MD, PhDSections of Adult and Pediatric Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Chicago, Chicago, IllinoisSearch for more papers by this author, Aaron N. Winn, PhDMedical College of Wisconsin, Milwaukee, WisconsinSearch for more papers by this author, Elbert S. Huang, MD, MPHSection of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, IllinoisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L23-0007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE: We appreciate the points raised by Dr. Carriazo and colleagues and Dr. Hanna and associates, but these concerns are unlikely to change the main findings. As both comments suggest, it is challenging to maintain up-to-date cost-effectiveness analyses because new evidence is constantly emerging. However, our model compared cascades of care; therefore, changes in the effectiveness of these drugs will have small effects on overall results.In regard to Dr. Carriazo and colleagues' comment, our study already models an improvement in estimated glomerular filtration rate for SGLT2 inhibitors; this translates in the model to a benefit in end-stage renal ... Author, Article, and Disclosure InformationAuthors: Neda Laiteerapong, MD, MS; Jason Alexander, MD; Louis Philipson, MD, PhD; Aaron N. Winn, PhD; Elbert S. Huang, MD, MPHAffiliations: Section of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, IllinoisSection of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, IllinoisSections of Adult and Pediatric Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Chicago, Chicago, IllinoisMedical College of Wisconsin, Milwaukee, WisconsinDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-2941. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFirst-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Jin G. Choi , Aaron N. Winn , M. Reza Skandari , Melissa I. Franco , Erin M. Staab , Jason Alexander , Wen Wan , Mengqi Zhu , Elbert S. Huang , Louis Philipson , and Neda Laiteerapong Metrics April 2023Volume 176, Issue 4KeywordsAtherosclerotic cardiovascular diseaseDiabetes mellitusHbA1cLife expectancyMarkov modelsMedical risk factorsQuality adjusted life expectancyQuality adjusted life yearsQuality of lifeType 2 diabetes ePublished: 18 April 2023 Issue Published: April 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...